Biofrontera AG (XTER:B8FK) Interest Expense : €-0.01 Mil (TTM As of Dec. 2023)

View and export this data going back to 2007. Start your Free Trial

What is Biofrontera AG Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Biofrontera AG's interest expense for the three months ended in Dec. 2023 was € -0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2023 was €-0.01 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Biofrontera AG's Operating Income for the three months ended in Dec. 2023 was € 0.65 Mil. Biofrontera AG's Interest Expense for the three months ended in Dec. 2023 was € -0.00 Mil. Biofrontera AG's Interest Coverage for the quarter that ended in Dec. 2023 was 217.33. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biofrontera AG Interest Expense Historical Data

The historical data trend for Biofrontera AG's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biofrontera AG Interest Expense Chart

Biofrontera AG Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-2.71

-3.08

-3.72

-0.16

-0.02

Biofrontera AG Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Interest Expense	Get a 7-Day Free Trial															-0.03	-0.01	-	-	-

Biofrontera AG Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.01 Mil.

Biofrontera AG (XTER:B8FK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Biofrontera AG's Interest Expense for the three months ended in Dec. 2023 was €-0.00 Mil. Its Operating Income for the three months ended in Dec. 2023 was €0.65 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Dec. 2023 was €0.68 Mil.

Biofrontera AG's Interest Coverage for the quarter that ended in Dec. 2023 is calculated as

Interest Coverage	=	-1	*	Operating Income (Q: Dec. 2023 )	/	Interest Expense (Q: Dec. 2023 )
	=	-1	*	0.652	/	-0.003
	=	217.33

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Biofrontera AG has enough cash to cover all of its debt. Its financial situation is stable.

Biofrontera AG (XTER:B8FK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biofrontera AG (XTER:B8FK) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

B8F:Germany B8F:Germany B8F:Germany

Address

Hemmelrather Weg 201, Leverkusen, NW, DEU, 51377

Website

https://www.biofrontera.com

Biofrontera AG is active in the field of healthcare. It manufactures pharmaceutical products, especially medical cosmetics and dermatological drugs for the care and treatment of skin diseases. Its suite of products includes the prescription drugs Ameluz and BF-RhodoLED, for the treatment of actinic keratosis and Belixos, for the regenerative care of reddened and inflamed skin.

Biofrontera AG (XTER:B8FK) Headlines

No Headlines